v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Revenues $ 34,469 $ 23,469 $ 93,419 $ 64,324
Cost of revenues [1] 8,534 4,548 21,811 12,359
Research and development [1] 7,312 5,342 24,276 16,698
Sales and marketing [1] 13,726 8,689 38,397 23,366
General and administrative [1] 9,046 3,982 30,456 10,561
Depreciation, amortization and impairment 1,882 156 3,481 487
Operating (loss) profit (6,031) 752 (25,002) 853
Finance expenses (income), net 4,962 707 (10,655) 3,878
(Loss) profit before taxes (10,993) 45 (14,347) (3,025)
Taxes on income 839 304 634 829
Net loss (11,832) (259) (14,981) (3,854)
Accretion of preferred stock to redemption value 0 (8,189) 0 (52,993)
Net loss attributable to common stockholders, basic (11,832) (8,448) (14,981) (56,847)
Net loss attributable to common stockholders, diluted $ (11,832) $ (8,448) $ (14,981) $ (56,847)
Net loss per stock attributable to common stockholders        
Basic (in dollars per share) [2] $ (0.09) $ (0.45) $ (0.12) $ (4.32)
Diluted (in dollars per share) [2] $ (0.09) $ (0.45) $ (0.12) $ (4.32)
Weighted-average number of stocks used in computing net loss per stock attributable to common stockholders        
Basic (in shares) [2] 132,959,511 18,849,710 129,768,724 13,157,022
Diluted (in shares) [2] 132,959,511 18,849,710 129,768,724 13,157,022
[1] Exclusive of depreciation and amortization presented separately.
[2] Prior period results have been adjusted to reflect the exchange of Innovid Inc’s common stock for Innovid Corp’s common stock at an exchange ratio of approximately 1.337 because of the Transaction. See Note 3 for further details.

Source